The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy

References

• Bray F, Ferlay J, Jacques F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373.
   PubMed Web of Science ®Google Scholar
• Rustgi AK, El-Serag HB, Ingelfinger JR. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509.
   PubMed Web of Science ®Google Scholar
• Hong Y, Ding Z. PD-1 inhibitors in the advanced esophageal cancer. Front Pharmacol. 2019;10:1418.
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517.
   PubMed Web of Science ®Google Scholar
• Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol. 1992;22:172-6.
   Google Scholar
• NCCN Clinical Practice Guidelines in oncology (NCCN guidelines®) esophageal and esophagogastric junction cancers version 3.2021. [cited 17 Jul 2021]. Availablefrom: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
   Google Scholar
• Kitagawa K, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017. Eds. the Japan esophageal society: part1. Esophagus: 2019; Vol. 16. 1–24. Available from:https://www.esophagus.jp/private/guideline/
   Google Scholar
• Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v50–v57.
   PubMed Web of Science ®Google Scholar
• Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2020;38(35):4138–4148.
   PubMed Web of Science ®Google Scholar
• Hayashi K, N Ando, H Watanabe, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419-23.
   Google Scholar
• Hiramoto S, Kato K, Shoji H, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.Int. J Clin Oncol. 2018;23:466–472.
   Web of Science ®Google Scholar
• Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–1220.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133.
   PubMed Web of Science ®Google Scholar
• Bando H, Shimodaira H, Fujitani K, et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer. 2018;91:86-91.
   Google Scholar
• Janowitz T, Thuss-Patience P, Marshall A, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer. 2016;114(4):381–387.
   PubMed Web of Science ®Google Scholar
• Edward C, Vincent D Physicians’ cancer chemotherapy drug manual 2020.
   Google Scholar
• Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–1272.
   PubMed Web of Science ®Google Scholar
• Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–959.
   PubMed Web of Science ®Google Scholar
• Morizato A, Shitara K, Chihiro Kondo C, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology. 2011;81(3–4):237–242.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260(27):14873–14878. https://www.ncbi.nlm.nih.gov/books/NBK548037/
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722–1726.
   PubMed Web of Science ®Google Scholar
• Irinotecan - LiverTox - NCBI Bookshelf (nih.gov). [cited 7 Jul 2021]. https://www.ncbi.nlm.nih.gov/books/NBK548037/[ L
   Google Scholar
• Yamaguchi T, Iwasa S, Shoji H, et al. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric Cancer. 2019;22(4):778–784
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altés A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91(4):678–682.
   PubMed Web of Science ®Google Scholar
• Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011;102(10):1868–1873.
   PubMed Web of Science ®Google Scholar
• Burkart C, Bokemeyer C, Klump B, et al. A phase ii trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007;27(4C):2845–2848.
   PubMed Web of Science ®Google Scholar
• Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis. 2003;18(4):330–334.
   PubMed Web of Science ®Google Scholar
• Ardolino L, Joshua A. Immune checkpoint inhibitors in malignancy. Aust Prescr. 2019;42(2):62–67.
   PubMed Web of Science ®Google Scholar
• Michael P, Robert S, Matthew H. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Yucai W, Shouhao Z, Fang Y, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019.
   PubMed Web of Science ®Google Scholar
• Weilei H, Guosheng W, Yian W, et al. Uncoupling therapeutic efficacy from immune-related adverse events in immune checkpoint blockade. iScience. 2020;23(10):101580.
   PubMed Web of Science ®Google Scholar
• Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631–639.
   PubMed Web of Science ®Google Scholar
• Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5(4):546–550.
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–842.
   PubMed Web of Science ®Google Scholar
• Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 2018;24(6):1296–1304.
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah M. Pembrolizumab plus chemotherapy versus chemotherapy for first-line, advanced esophageal cancer: the randomized, placebo-controlled phase 3 KEYNOTE-590 study. Lancet 2021. in press.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. S0140-6736(21) 00797-2.
   PubMed Web of Science ®Google Scholar
• Hellmann M, Paz-Ares L, Caro B, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Janjigian Y, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 2018;36(28):2836–2844.
   PubMed Web of Science ®Google Scholar
• Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J Clin Oncol. 2021;39(suppl 15): abstr LBA4001. doi:https://doi.org/10.1200/JCO.2021.39.15_suppl.LBA4001.
   Google Scholar
• Nanda R, Liu M, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kato K, Daiko H, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B. J Clin Oncol. 2021;39(suppl):202.doi: https://doi.org/10.1200/JCO.2021.39.3_suppl.202.
   PubMedGoogle Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203.
   PubMed Web of Science ®Google Scholar